Cencora is a pharmaceutical wholesaler that distributes branded and generic medicines, specialty drugs and related products, and provides services to pharmaceutical manufacturers. It also dispenses healthcare products and, through recent acquisitions and investments, operates practice-management and physician specialty network organisations, including management services organisations.
Its customers include retail pharmacies, chain drugstores, hospitals, specialty community physician practices such as oncology and retina specialists, health insurers and 340B covered entities. Most buy on credit, with creditworthiness assessed case by case. The company earns money chiefly by selling pharmaceuticals and services, and through arrangements with suppliers such as distribution service fees, chargebacks and returns. Its two largest customer receivable balances are Walgreens and Boots together and Evernorth Health Services.
The business is conducted through a variety of operations spanning distribution, dispensing and industry services, with activities in the United States, the United Kingdom, the European Union and other countries. Cencora is one of three national pharmaceutical distributors that negotiated the Distributor Settlement Agreement resolving most opioid lawsuits brought by state and local governments, effective April 2022.
Based on Cencora's 10-K filed November 25, 2025.
